Basilea Pharmaceutica

Basilea Pharmaceutica

Basilea Pharmaceutica is a public European biotech company listed on the SIX Swiss exchange under the ticker BSLN.SW As of Dec 13th 2011 it shows a market cap of CHF 315M (USD $333M). From its last financial report (6 months ended June 2011), it sits on CHF 243M cash, the debt/equity ratio is 0.44 and net loss is CHF 20M Basilea is currently developing several products in the anti-infective area and has one product commercialized for the treatment of chronic hand eczema (CHE) in a number of countries in parntership with global pharmaceutical companies. (Article originally published in December 2011)

[Read more...]

Update on Cytokinetics

Update on Cytokinetics

Main remarks from Cytokinetics Inc. (Nasdaq: CYTK) last PRs and quarterly results are:

- Data from the phase II trial of ‘357 in myasthenia gravis are delayed until 1H of 2012.

- Amgen (Nasdaq: AMGN) is continuing the development of  Omecamtiv mercabil (OM) in its phase IIb safety and efficacy trial, now dubbed ATOMIC-AHF. Remember that top-line data won’t be released until 1H 2013.

- Cytokinetics is collecting data from a Part A study of its phase II PK, PD, multiple dose, safety and tolerability trial of ‘357 in patients with ALS who are not getting riluzole. Data will be presented at the 22nd International Symposium on ALS and Motor Neurone Diseases Meeting in Sydney, Australia on November 30 – December 2. It initiated a Part B in patients who are also receiving riluzole on Nov 1 with results expected in 1H of 2012

[Read more...]

Incyte

Incyte

The main short term catalyst for Incyte Pharmaceuticals (Nasdaq: INCY) is a PDUFA date of Dec 3 for its JAK1/JAK2 inhibitor ruxolinitib -ruxo for short. This drug met its primary and secondary endpoints in two pivotal Phase III trials named COMFORT I and COMFORT II. In both trials patients treated in the ruxo arm experienced significant spleen reduction as well as clinically meaningful improvements of symptoms and quality of life. These trials were conducted under a Special Protocol Assessment with the FDA.

[Read more...]

Brief note on Ariad Pharmaceuticals going into the ASH meeting, Dec 10-13

Brief note on Ariad Pharmaceuticals going into the ASH meeting, Dec 10-13

(As published on Seeking Alpha on Nov 3 2011, click here to read the post and additional comments)

Ariad Pharmaceuticals’ $1.5bn market cap is mainly driven by two drugs in advanced clinical stages: ridaforolimus for soft tissue and bone sarcoma and ponatinib for chronic myeloid leukemia (CML) and Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL). The former is partnered with Merck and presented top-line results of the phase III SUCCEED trial early this year. Merck is now on track to file an NDA later this year. Ariad also announced on August 18 that the EMA had accepted the MAA of the drug.

[Read more...]